D.R. and J.V. share first co-authorship.
Cirrhosis and Liver Failure
Oral probiotic VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites
Article first published online: 4 APR 2014
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Volume 34, Issue 10, pages 1504–1512, November 2014
How to Cite
Liver Int. 2014; 34: 1504–1512
- Issue published online: 13 OCT 2014
- Article first published online: 4 APR 2014
- Accepted manuscript online: 24 MAR 2014 12:16PM EST
- Manuscript Accepted: 16 MAR 2014
- Manuscript Received: 24 JAN 2014
- Fondo de Investigación Sanitaria-ISCIII. Grant Number: FIS06/0703
- Fundación Mutua Madrileña. Grant Number: FMM-2009
- MINECO. Grant Number: R&C-2010-05838
Figure S1. Overall (box-plots) and individual (connecting lines) changes of plasma lipopolysaccharide-binding protein (LBP) in nine patients with cirrhosis and ascites before and after a 6 week course of probiotic VSL#3 supplementation
Figure S2. Overall (box-plots) and individual (connecting lines) changes of plasma IL-6 in nine patients with cirrhosis and ascites before and after a 6 week course of probiotic VSL#3 supplementation.
Figure S3. Overall (box-plots) and individual (connecting lines) changes of the hepatic venous pressure gradient (HVPG) in a cohort of 30 patients with compensated chronic hepatitis C, METAVIR score F3/F4 stage and HVPG >5 mmHg who underwent two hepatic haemodynamic studies separated by a period of 12–36 months in our institution. These patients did not receive antiviral therapy or therapy with β-blockers and the haemodynamic studies were performed between January 1998 and December 2002. The dotted line represents the 12 mmHg HVPG threshold.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.